Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HighTide Completes Enrollment in US Phase II Trial of NASH Candidate

publication date: Oct 23, 2019

HighTide Therapeutics, a Shenzhen-Maryland biopharma, reported it has completed enrollment in a US Phase IIa trial of its novel NASH treatment. The double-blind, dose-ranging trial will assess the efficacy and safety of HTD1801 in adults with NASH and type 2 diabetes. HighTide develops novel drugs to treat chronic liver diseases, gastrointestinal diseases and metabolic disorders. HTD1801, the company’s lead candidate, is a first-in-class new molecular entity in trials to treat primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The FDA has granted HTD1801 Fast Track Designation for both diseases. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital